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Abstract MRL mice bearing the lpr (Fas) or gld (Fas ligand)
mutation, MRL-Faslpr or MRL-FasLgld , respectively, develop
arthritis similar to rheumatoid arthritis, but C3H and C57BL/6
mice bearing such mutations do not. In MRL-Faslpr mice,
agalactosylated oligosaccharides in serum IgG increase signifi-
cantly in comparison to MRL-+/+ mice without arthritis. In this
study, an increased level of agalactosylation in IgG, as compared
to MRL-+/+, was found in both MRL-Faslpr and MRL-FasLgld
mice. In contrast, the incidence of IgG without galactose was
comparable among C3H-Faslpr, C3H-FasLgld , and C3H-+/+
mice as well as between C57BL/6-Faslpr and C57BL/6-+/+
mice. These results suggest that the increase in agalactosylated
IgG and the development of arthritis in MRL-Faslpr and
MRL-FasLgld mice are controlled by the MRL genetic
background. ß 2001 Federation of European Biochemical So-
cieties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
MRL-Faslpr and MRL-FasLgld mice are known to sponta-
neously develop an autoimmune arthritis similar to rheuma-
toid arthritis (RA) [1^3]. Faslpr (Fas gene with the lpr muta-
tion) and FasLgld (Fas ligand gene with the gld mutation)
induce a de¢cit in Fas/FasL-mediated apoptosis [4,5], which
is signi¢cantly related to the development of arthritis in MRL
mice [6]. In contrast, C3H-Faslpr, C3H-FasLgld and C57BL/6-
Faslpr mice do not develop arthritis in spite of a de¢cit of Fas/
FasL-mediated apoptosis [3]. Therefore, an MRL genetic
background is a prerequisite for the development of arthritis
in addition to abnormal apoptosis [6].
Mouse IgG oligosaccharide chains consist of a series
of biantennary complex-type structures of þ GalL1-4-
GlcNAcL1-2ManK1-6( þ GalL1-4GlcNAcL1-2ManK1-3)Man-
L1-4GlcNAcL1-4( þ FucK1-6)GlcNAc containing zero to two
sialic acid residues linked to Gal residues [7]. The incidence of
agalactosylated oligosaccharide chains signi¢cantly increases
in serum IgG of MRL-Faslpr mice in comparison to that of
age-matched control congenic MRL-+/+ mice with no arthri-
tis [8]. A similar abnormality in IgG galactosylation has been
observed in RA patients [9]. However, the mechanism of the
aberrant existence of agalactosylated IgG and its pathogenic
signi¢cance in the development of arthritis are still poorly
understood.
In order to better understand the relationship between the
abnormality in IgG galactosylation, the functional defects in
Fas/FasL-mediated apoptosis, and the development of arthri-
tis, we conducted a comparative study of the abnormality in
IgG galactosylation in mice with di¡erent genetic back-
grounds and with or without Faslpr and FasLgld .
2. Materials and methods
2.1. Mice
MRL-Faslpr, MRL-+/+, C3H-Faslpr, C3H-FasLgld , C3H-+/+,
C57BL/6 (B6)-Faslpr, and B6-+/+ mice were originally purchased
from The Jackson Laboratory (Bar Harbor, ME, USA). MRL-
FasLgld mice were produced as described elsewhere [3]. The mice
were housed under conditions free of speci¢c pathogens. Sera (100^
200 Wl/mouse) were obtained from 10 mice at 6 months of age and
pooled according to the mouse strain. Development of arthritis in
MRL-Faslpr and MRL-FasLgld mice had been con¢rmed via histopa-
thological study in knee and/or foot joints, characterized by synovial
lining proliferation and/or granulomatous in£ammation in the syno-
vial tissue as described previously [10]. No arthritis was observed in
the other mice.
2.2. Puri¢cation of IgG from sera
Each serum sample (1^2 ml) was diluted with 9 volumes of 1.5 M
glycine^NaOH bu¡er, pH 8.9, containing 3 M NaCl, and ¢ltered.
Then, total IgG in the serum sample was bound to a protein A-Seph-
arose CL-4B column (1.0U6.5 cm; Pharmacia Biotech, Uppsala,
Sweden) equilibrated with the same bu¡er and eluted with 0.1 M
sodium citrate bu¡er, pH 3.0 [11], followed by further puri¢cation
by gel ¢ltration chromatography using a Sephacryl S-300 column
(2.5U90 cm; Pharmacia Biotech). The purity of IgG samples was
con¢rmed by SDS^PAGE using the Laemmli system [12] under re-
ducing and non-reducing conditions and Ouchterlony double immu-
nodi¡usion assay using antisera against murine IgG, IgM, IgA, and
whole serum. The puri¢ed IgG samples were exhaustively dialyzed
against distilled water and then lyophilized.
2.3. Analyses of structures of N-linked oligosaccharides from
IgG samples
Puri¢ed IgG samples (2^3 mg) were subjected to gas-phase hydra-
zinolysis at 90‡C for 3 h using Hydraclub S204 (Honen, Tokyo, Ja-
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pan) followed by N-acetylation to quantitatively liberate N-linked oli-
gosaccharides [13]. The oligosaccharide mixture was puri¢ed with
cellulose column chromatography [14] and then derivatized with
p-aminobenzoic acid ethyl ester (ABEE; Wako Pure Chemical Indus-
tries, Osaka, Japan) by reductive amination [15,16].
Analyses of the IgG-derived ABEE-oligosaccharides were per-
formed using high-performance liquid chromatography (HPLC).
Anion exchange and reversed-phase HPLC were carried out using a
Cosmogel DEAE column (0.75U7.5 cm; Nacalai Tesque, Kyoto, Ja-
pan) and a Wakosil 5C18-200 column (0.46U25 cm; Wako Pure
Chemical Industries), respectively, as described previously [15,16].
Elution of ABEE-oligosaccharides was monitored at 304 nm. Mass
spectrometry analysis of ABEE-oligosaccharides was performed with
a MALDI-TOF mass spectrometer, model Vision 2000 (ThermoBio-
Analysis, Hemel Hempsted, UK).
2.4. Oligosaccharides and enzymes
Neutral, monosialyl, and disialyl biantennary ABEE-oligosaccha-
rides, þ NeuAcK2-6GalL1-4GlcNAcL1-2ManK1-6( þ NeuAcK2-6Gal-
L1-4GlcNAcL1-2ManK1-3)ManL1-4GlcNAcL1-4GlcNAc-ABEE, were
prepared from oligosaccharides of human ¢brinogen [17] by ABEE
derivatization as described above. ABEE-oligosaccharides 1^8, with
the same structures as oligosaccharides a^h shown in Fig. 3, respec-
tively, were prepared from oligosaccharides of human ¢brinogen and
human IgG [17,18] by means of ABEE-derivatization. ABEE-oligo-
saccharides 9 and 10 with the respective structures ManK1-6(Man-
K1-3)ManL1-4GlcNAcL1-4GlcNAc-ABEE and ManK1-6(ManK1-3)-
ManL1-4GlcNAcL1-4(FucK1-6)GlcNAc-ABEE were prepared from
ABEE-oligosaccharides 1 and 5, respectively, by digestion with a mix-
ture of L-galactosidase and L-N-acetylhexosaminidase. Digestion of
ABEE-oligosaccharides was performed at 37‡C in a toluene atmos-
phere for 16 h using Arthrobacter ureafaciens neuraminidase (Nacalai
Tesque), Diplococcus pneumoniae L-galactosidase (Boehringer Mann-
heim, Mannheim, Germany), or D. pneumoniae N-acetyl-L-glucosami-
nidase (Boehringer Mannheim) as described previously [15,16].
2.5. Statistical analysis
Statistical analysis, Student’s t-test, was performed with a Macin-
tosh computer (PowerBook G4 from Apple Japan, Tokyo, Japan)
using software titled StatMate III for Macintosh (ATMS, Tokyo,
Japan).
3. Results
3.1. Analysis of murine IgG oligosaccharides by charge
The total IgG fractions were puri¢ed from sera of MRL-
Faslpr, MRL-FasLgld , MRL-+/+, C3H-Faslpr, C3H-FasLgld ,
C3H-+/+, B6-Faslpr, and B6-+/+ mice. Oligosaccharides of
these IgG samples were then prepared and derivatized with
ABEE as described in Section 2. To determine the charges of
IgG oligosaccharides, ABEE-oligosaccharide fractions ob-
tained from all IgG samples were subjected to ion exchange
HPLC with a Cosmogel DEAE column. Each ABEE-oligo-
saccharide fraction yielded one major neutral (N) and two
minor acidic (A1 and A2) fractions as shown in Fig. 1. Since
the elution positions of A1 and A2 corresponded to those of
authentic monosialyl and disialyl biantennary ABEE-oligosac-
charides, respectively, and since they were converted to neu-
tral oligosaccharides by sialidase treatment (data not shown),
A1 and A2 were respectively noted to be monosialylated and
disialylated ABEE-oligosaccharides. Molar ratios of N, A1,
and A2 calculated on the basis of their absorbance at 304
nm have been summarized in Table 1. MRL-Faslpr and
MRL-FasLgld mice with arthritis displayed a slightly higher
incidence of neutral oligosaccharides in comparison to MRL-
+/+ mice without arthritis. All other mice with or without
Faslpr or those having FasLgld with no arthritis displayed a
comparable ratio.
3.2. Structural analyses of desialylated oligosaccharides from
murine IgG
To analyze the oligosaccharide structure of IgG samples,
desialylated neutral ABEE-oligosaccharide mixtures obtained
by exhaustive sialidase treatment followed by puri¢cation with
anion exchange HPLC were subjected to reversed-phase
Table 1
Percent molar ratios of various oligosaccharide structures of serum IgG from various strains of mice
Mice Arthritis Sialylated glycoforms (%) Galactosylated glycoforms (%)
N A1 A2 G0 G1 G2
MRL-+/+ 3 84.7 þ 0.5 13.0 þ 0.3 2.3 þ 0.1 29.2 þ 0.3 48.6 þ 0.6 22.2 þ 0.5
MRL-Faslpr + 92.2 þ 0.6 6.5 þ 0.5 1.3 þ 0.2 51.0 þ 3.0 41.7 þ 1.4 7.3 þ 3.0
MRL-FasLgld + 91.4 þ 1.8 7.0 þ 1.2 1.6 þ 0.5 46.2 þ 3.0 41.8 þ 0.6 12.0 þ 3.6
C3H-+/+ 3 90.3 þ 1.0 6.8 þ 0.8 2.9 þ 0.2 34.5 þ 3.0 47.3 þ 0.5 18.2 þ 2.6
C3H-Faslpr 3 91.4 þ 0.8 7.4 þ 0.8 1.2 þ 0.1 38.8 þ 3.3 47.9 þ 2.6 13.3 þ 0.8
C3H-FasLgld 3 91.5 þ 0.9 7.3 þ 0.6 1.2 þ 0.3 37.5 þ 0.8 49.2 þ 0.6 13.3 þ 0.3
B6-+/+ 3 84.4 þ 1.0 12.9 þ 1.2 2.7 þ 0.3 31.6 þ 1.7 39.9 þ 0.9 28.5 þ 0.9
B6-Faslpr 3 86.9 þ 1.6 11.5 þ 1.4 1.6 þ 0.4 34.1 þ 1.2 43.6 þ 0.8 22.3 þ 1.2
N, A1, and A2 denote non-, mono-, and disialyloligosaccharides, respectively. G0, G1, and G2 denote oligosaccharides with zero, one, and two
galactose residue(s), respectively. The percentages of sialylated or galactosylated glycoforms were calculated on the basis of their absorbance at
304 nm in ion exchange or reversed-phase HPLC, respectively. This study was repeated three times and values are indicated as the mean þ
S.E.M. of the three pooled sera.
Fig. 1. Elution pro¢le of ABEE-oligosaccharides from mouse IgG
sample in anion exchange HPLC. An ABEE-oligosaccharide mixture
from an IgG sample of MRL-FasLgld mice was subjected to anion
exchange HPLC with a Cosmogel DEAE column (0.75U7.5 cm).
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HPLC with a Wakosil 5C18-200 column. As shown in Fig. 2,
the ABEE-oligosaccharide mixtures of an IgG sample ob-
tained from MRL-FasLgld yielded eight oligosaccharide frac-
tions (a^h in Fig. 2). The ABEE-oligosaccharide mixtures of
those obtained from all other strains also yielded eight oligo-
saccharide fractions, although the ratios of the fractions dif-
fered among the IgG samples. The elution positions of oligo-
saccharide fractions a^h corresponded to those of a series of
authentic biantennary complex-type oligosaccharides 1^8 with
the structures þ GalL1-4GlcNAcL1-2ManK1-6( þ GalL1-4-
GlcNAcL1-2ManK1-3)ManL1-4GlcNAcL1-4( þ FucK1-6)Glc-
NAc-ABEE, respectively.
The structures of the respective IgG-derived ABEE-oligo-
saccharides were analyzed using sequential exoglycosidase di-
gestion followed by reversed-phase HPLC. Conversion of the
eight ABEE-oligosaccharide fractions a^h into two oligosac-
charide fractions d and h was observed upon incubation with
L-galactosidase (data not shown). After sequential digestion
with L-galactosidase and N-acetyl-L-glucosaminidase, eight
ABEE-oligosaccharide fractions were converted into two oli-
gosaccharide fractions eluting at the same positions as authen-
tic ABEE-oligosaccharides 9 and 10 with the structures
ManK1-6(ManK1-3)ManL1-4GlcNAcL1-4GlcNAc-ABEE and
ManK1-6(ManK1-3)ManL1-4GlcNAcL1-4(FucK1-6)GlcNAc-
ABEE, respectively (data not shown). The behavior of the
oligosaccharides in fractions a^h on the reversed-phase
HPLC column and the results of the sequential exoglycosidase
treatment suggested that structures of the ABEE-oligosaccha-
rides a^h derived from each IgG sample were as shown in Fig.
3. These results were also con¢rmed by analysis of these eight
ABEE-oligosaccharide fractions with MALDI-TOF mass
spectrometry (data not shown).
The molar ratios of oligosaccharides a^h in each IgG sam-
ple were calculated on the basis of their absorbance at 304
nm. Levels of incidence of fucosylated oligosaccharides were
similar (90^95%) among IgG samples. In contrast, those of
galactosylated oligosaccharides di¡ered (see below). Inciden-
ces (in percent) of oligosaccharides G0 (d and h in Fig. 3), G1
(b, c, f, and g in Fig. 3), and G2 (a and e in Fig. 3) with zero,
one, and two galactose residues, respectively, are summarized
in Table 1.
3.3. IgG galactosylation in various strains of mice
Relative contents of the agalactosylated oligosaccharides
were compared among IgG samples from strains with the
same genetic background to elucidate the relationship in terms
of the presence of Faslpr or FasLgld and the development of
arthritis. The incidences of oligosaccharides without a galac-
tose residue, G0, in IgG samples derived from MRL mice
bearing Faslpr, which have arthritis, increased signi¢cantly
(P6 0.002) in comparison to those derived from MRL-+/+
mice without arthritis (Table 1). The same signi¢cant increase
(P6 0.005) in the incidence of G0 oligosaccharides was found
in MRL mice bearing FasLgld , which also have arthritis (Table
1). However, no signi¢cant di¡erence in the incidence of G0
oligosaccharides was observed among C3H-Faslpr, C3H-
FasLgld , and C3H-+/+ (Ps 0.38), and between B6-Faslpr and
B6-+/+ (Ps 0.29), all of which do not develop arthritis (Table
1). The incidence of oligosaccharides with two galactose res-
idues, G2, in IgG samples from C3H-Faslpr and C3H-FasLgld
mice decreased to about 70% of that in C3H-+/+ mice as in
the case of MRL-Faslpr and MRL-FasLgld mice, where the
incidence decreased to one-third and half of that in MRL-+/
+ mice. However, statistical analyses indicated that the de-
crease in G2 incidence in C3H mice was not signi¢cant
(Ps 0.13) while the decrease in MRL-Faslpr and MRL-
Fig. 3. Structures of ABEE-oligosaccharides a^h derived from IgG
samples.
Fig. 2. Elution pro¢le in reversed-phase HPLC of desialylated neu-
tral ABEE-oligosaccharides from mouse IgG sample. A desialylated
neutral ABEE-oligosaccharide mixture from the IgG sample of
MRL-FasLgld mice was subjected to reversed-phase HPLC with a
Wakosil 5C18-200 column (0.46U25 cm). The numbered arrows at
the top of the ¢gure indicate the elution positions of authentic
ABEE-oligosaccharides. Structures of these authentic oligosaccha-
rides are described in Section 2.
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FasLgld was signi¢cant (P6 0.01 and P6 0.05, respectively).
The decrease in the incidence of sialylated oligosaccharides as
found in MRL-Faslpr and MRL-FasLgld mice (Table 1) may
be explained by the decrease in galactosylation of IgG oligo-
saccharides.
When the level of agalactosylation in each IgG sample was
calculated as the ratio of non-galactosylated oligosaccharide
G0 to galactosylated oligosaccharides G1 plus G2, MRL-
Faslpr mice displayed a marked increase (P6 0.01) in the level
of agalactosylation when compared to MRL-+/+ mice (Fig.
4A); this result was consistent with previous reports [8]. The
level of IgG agalactosylation in MRL-FasLgld mice also in-
creased (P6 0.02) comparably to that in MRL-Faslpr mice
(Fig. 4A), indicating that MRL-FasLgld mice, as well as
MRL-Faslpr mice, exhibit an abnormality in IgG galactosyla-
tion. On the other hand, no signi¢cant di¡erence (Ps 0.38)
was observed in the level of agalactosylation for C3H-+/+,
C3H-Faslpr, and C3H-FasLgld mice; similarly, no signi¢cant
di¡erence (Ps 0.29) was observed for B6-Faslpr and B6-+/+
mice (Fig. 4B,C).
4. Discussion
The present study led to two signi¢cant conclusions with
regard to the expression of the abnormality in IgG galactosy-
lation. First, the expression of the abnormality in IgG galac-
tosylation in MRL-Faslpr mice is not due to the lpr genotype
itself but to the functional defect of Fas/FasL-mediated apo-
ptosis since this abnormality was also observed in MRL-
FasLgld mice. Second, the MRL genetic background is in-
volved in the expression of the abnormal IgG galactosylation
in addition to the presence of Faslpr or FasLgld since this
abnormality was not observed in IgG samples from C3H-
Faslpr, C3H-FasLgld , or B6-Faslpr mice. It has been demon-
strated that the development of arthritis in MRL-Faslpr and
MRL-FasLgld mice is controlled by the MRL genetic back-
ground [6]. Taken together with the present results, abnormal
IgG galactosylation, like arthritis, occurs with a combination
of a de¢cit in Fas/FasL-mediated apoptosis and an MRL
genetic background and is thus related to the development
of arthritis in MRL mice with abnormal apoptosis.
It has been reported that IgG was galactosylated di¡erently
among the IgG subclasses in mice with collagen-induced ar-
thritis [19]. It was also indicated that degalactosylation of IgG
delayed the clearance of IgG, particularly IgG2a, from sera of
several strains of mice including MRL mice [20]. It should be
noted that the IgG samples used in this study were the total
IgG fractions of murine sera, which were eluted from the
protein A-Sepharose column with sodium citrate bu¡er, pH
3.0, according to the methods described [11]. Therefore, aga-
lactosylation levels in these IgG samples may have been af-
fected by the delay in clearance of the particular subclass of
IgG which may be involved in the pathogenesis. Analyses of
the oligosaccharide structures with regard to IgG subclasses
would be helpful in elucidating the possible e¡ects of this
delay, although the current study did not determine the pop-
ulation of IgG subclasses and their oligosaccharide structures.
Agalactosylated IgG can activate complements via interac-
tion with mannose-binding lectin [21], which can bind to non-
reducing terminal GlcNAc residues in agalactosylated IgG
oligosaccharides [22] and lectin is a ligand of complement
receptor 1 [23], which is involved in phagocytosis and clear-
ance of immune complexes [24]. These processes might be
e¡ective for opsonization and elimination of immune com-
plexes in host immune responses. However, the excessive
and dysregulated existence of agalactosylated IgG in serum
occurring in MRL mice with abnormal apoptosis and in pa-
tients with RA could have signi¢cant immunopathological
consequences. Autoantibodies produced by activated auto-
reactive B cells that escaped from Fas/FasL-mediated apopto-
sis, aberrantly agalactosylated under the control of MRL
background genes, may cause signi¢cant development of tis-
sue lesions. A recent report has demonstrated that oligosac-
charides of IgG rheumatoid factor derived from patients with
RA were aberrantly agalactosylated [16]. In light of this fact,
the aberrant amount of agalactosylated IgG autoantibodies in
serum that is characteristic of MRL mice might be responsible
for the disease development occurring selectively in an MRL
strain.
Recent genetic studies of MRL-Faslpr mice have indicated
that several gene loci with the MRL alleles are related to the
development of autoimmune diseases in a polygenic manner
[10,25^28], although the natures of their gene products remain
unclear. Among the genes involved in the MRL genetic back-
ground, a certain gene may be present to a¡ect the expression
and activity of galactosyltransferase involved in IgG galacto-
sylation in cooperation with the Faslpr and FasLgld genes.
Recently, we found the occurrence of abnormal IgG galac-
Fig. 4. Comparison of IgG agalactosylation levels among various mice with di¡erent genetic backgrounds. Agalactosylation levels, G0/
(G1+G2), of serum IgG in MRL (A), C3H (B), and B6 (C) mice without (+) or with the Faslpr gene (lpr) or the FasLgld gene (gld) were calcu-
lated as described in the text. Values are indicated as the mean þ S.E.M. of the three pooled sera. The presence or absence of the development
of arthritis in each strain of mice is shown at the bottom of the ¢gure.
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tosylation, similar to that in control MRL-Faslpr mice with
arthritis, in MRL-Faslpr mice depleted of CD4 T cells, which
failed to develop arthritis, suggesting that the abnormality in
IgG galactosylation does not arise as a consequence of disease
development [29]. Rather, this abnormality may act as an
accelerator in the development of arthritis, when considering
that arthritis in MRL-Faslpr mice is a multigenic disease [10].
Further study from the viewpoint of genomics is necessary to
elucidate the mechanism of the aberrant existence of agalac-
tosylated IgG and the role of agalactosylated IgG with regard
to disease progression in MRL mice with a de¢cit in Fas/
FasL-mediated apoptosis.
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